Friday, 16 October 2026European Markets

BELYSSE GROUP Stock Impressive Rise Before The Weekend, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with BELYSSE GROUP (BELYS.BR) rising 11.78% to €0.74 on Friday, following the last session's upward trend. BEL 20 rose 1.66% to €3,679.69, after two consecutive sessions in a row of losses, on what was an all-around bullish trend exchanging session today.

About BELYSSE GROUP

Belysse Group NV produces and sells textile floor coverings for commercial and residential applications in Europe, North America, and internationally. The company designs, manufactures, and distributes broadloom carpets and modular carpet tiles primarily for offices and public projects. It commercializes its products under the Bentley, modulyss, arc edition, and ITC brands. The company was formerly known as Balta Group NV and changed its name to Belysse Group NV in October 2022. Belysse Group NV was founded in 1964 and is headquartered in Waregem, Belgium. Belysse Group NV is a subsidiary of LSF9 Belysse Holdco S.à r.l.

Earnings Per Share

As for profitability, BELYSSE GROUP has a trailing twelve months EPS of €-0.45.

Volume

Today's last reported volume for BELYSSE GROUP is 3912 which is 41.72% below its average volume of 6713.

Volatility

BELYSSE GROUP's last week, last month's, and last quarter's current intraday variation average was a negative 2.59%, a negative 1.02%, and a positive 5.22%.

BELYSSE GROUP's highest amplitude of average volatility was 2.79% (last week), 4.64% (last month), and 5.22% (last quarter).

More news about BELYSSE GROUP (BELYS.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
BELYSSE GROUP Stock Impressive Rise Before The Weekend, Outperforms Market | ViaNews EU